Royalty Reduction. The royalties due to ALNYLAM under Section 3.9 above may be reduced on a country-by-country basis in the Territory by the amount of royalties paid or payable with respect to Necessary Third Party IP; provided, however, that royalties due to ALNYLAM under Section 3.9 may not be reduced by more than [**] of the royalties otherwise due (and will not in any case be reduced below [**] of the amount of royalties that would otherwise be due, e.g. for Net Sales up to and including [**] the minimum effective royalty rate would be [**]. For purposes of illustration only, if annual Net Sales of a PROTIVA Development Product are [**] and royalties due to Third Parties in respect of the sale of such product total [**] of Net Sales (or [**]), royalties due to ALNYLAM may be reduced only by [**] which is determined as follows: maximum reduction is [**] of the royalty due on Net Sales of [**], calculated by [**].
Appears in 2 contracts
Samples: Cross License Agreement (Tekmira Pharmaceuticals Corp), Cross License Agreement (Alnylam Pharmaceuticals, Inc.)
Royalty Reduction. The Any royalties due to ALNYLAM PROTIVA under Section 3.9 4.9 above may be reduced on a country-by-country basis in the Territory by the amount of royalties paid or payable with respect to Necessary Third Party IP; provided, however, that royalties due to ALNYLAM PROTIVA under Section 3.9 4.9 may not be reduced by more than [**] of the royalties otherwise due (and will not in any case be reduced below [**] of the amount of royalties that would otherwise be due, e.g. for Net Sales up to and including [**] the minimum effective royalty rate would be [**]). For purposes of illustration only, if annual Net Sales of a PROTIVA an ALNYLAM Development Product are [**] and royalties due to Third Parties in respect of the sale of such product total [**] of Net Sales (or [**]), royalties due to ALNYLAM PROTIVA may be reduced only by [**] ], which is determined as follows: maximum reduction is [**] one-third of the royalty due on Net Sales of [**], calculated by [**].
Appears in 2 contracts
Samples: Cross License Agreement (Tekmira Pharmaceuticals Corp), Cross License Agreement (Alnylam Pharmaceuticals, Inc.)
Royalty Reduction. The Any royalties due to ALNYLAM PROTIVA under Section 3.9 4.9 above may be reduced on a country-by-country basis in the Territory by the amount of royalties paid or payable with respect to Necessary Third Party IP; provided, however, that royalties due to ALNYLAM PROTIVA under Section 3.9 4.9 may not be reduced by more than [**] of the royalties otherwise due (and will not in any case be reduced below [**] of the amount of royalties that would otherwise be due, e.g. for Net Sales up to and including [**] the minimum effective royalty rate would be [**]). For purposes of illustration only, if annual Net Sales of a PROTIVA an ALNYLAM Development Product are [**] and royalties due to Third Parties in respect of the sale of such product total [**] of Net Sales (or [**]), royalties due to ALNYLAM PROTIVA may be reduced only by [**] ], which is determined as follows: maximum reduction is [**] one-third of the royalty due on Net Sales of [**], calculated by [**].
Appears in 1 contract
Samples: Cross License Agreement (TEKMIRA PHARMACEUTICALS Corp)
Royalty Reduction. The royalties due to ALNYLAM under Section 3.9 above may be reduced on a country-by-country basis in the Territory by the amount of royalties paid or payable with respect to Necessary Third Party IP; provided, however, that royalties due to ALNYLAM under Section 3.9 may not be reduced by more than [**] of the royalties otherwise due (and will not in any case be reduced below [**] of the amount of royalties that would otherwise be due, e.g. for Net Sales up to and including [**] the minimum effective royalty rate would be [**]). For purposes of illustration only, if annual Net Sales of a PROTIVA Development Product are [**] and royalties due to Third Parties in respect of the sale of such product total [**] of Net Sales (or [**]), royalties due to ALNYLAM may be reduced only by [**] which is determined as follows: maximum reduction is [**] of the royalty due on Net Sales of [**], calculated by [**].
Appears in 1 contract
Samples: Cross License Agreement (TEKMIRA PHARMACEUTICALS Corp)